Genentech was able to demonstrate in mouse models that the new bispecific antibody was able to reach therapeutic levels in the brain. Genentech's method of disguising and transporting the therapeutic antibody by attaching it to a receptor-mediated transcytosis activator has been referred to as the "Trojan Horse" method.
Genentech demonstrated in mouse models that the new bispecific antibody achieved therapeutic concentrations in the brain. The company's approach of hiding and delivering the therapeutic antibody via a receptor-mediated transcytosis activator, which it has dubbed the "Trojan Horse," is effective.